TruLeaf from the AllMeD Solutions group, successfully completed the first phase of a first-in-human clinical trial of a revolutionary system for tricuspid and mitral heart valve implantation via catheter only

CAESAREA, Israel, Sept. 10, 2025 /PRNewswire/ -- AllMeD Solutions (TASE: ALMD), which holds the Israeli biomedical company TruLeaf-Medical , announced the successful completion of stage 1 of the first human implantation of the innovative RoseDoc docking system for transcatheter replacement of the tricuspidvalve. This is a breakthrough system that replaces diseased heart valves and is inserted via catheter, without the need for open-heart surgery.

The procedure was successfully performed for the first time ever on September 5th, 2025 in India, using compassionate care pathway, on

See Full Page